10/16/2017 | CV | Market Commentary: Morning Commentary: Isis Pharmaceuticals notches another outright gain
|
7/6/2015 | CV | Market Commentary: Convertibles weaker in thin trading; energy issues indicated lower; Qihoo edges downward
|
6/30/2015 | CV | Market Commentary: Convertibles lower with month-end in focus; Impax slips below par; June primary falters
|
6/30/2015 | CV | Market Commentary: Morning Commentary: Convertibles lower again with month-end in focus; Isis Pharmaceuticals lower
|
6/19/2015 | SP | New Issue: Credit Suisse prices $1 million 15.5% autocallable yield notes on Isis Pharmaceuticals
|
5/20/2015 | SP | New Issue: JPMorgan prices $1 million autocallable reverse exchangeables on Isis
|
5/8/2015 | SP | New Issue: JPMorgan prices $1 million autocallable reverse exchangeables on Isis Pharmaceuticals
|
5/4/2015 | PP | Market Commentary: New Source launches; Isis adds on swap; Ares Capital steady to mixed after earnings miss
|
5/4/2015 | CV | Market Commentary: New Source launches; Isis adds on swap; Ares Capital steady to mixed after earnings miss
|
4/9/2015 | PP | Market Commentary: Qihoo, other Asian internet names up again in active trade; Isis improves; Teva at parity
|
4/9/2015 | CV | Market Commentary: Qihoo, other Asian internet names up again in active trade; Isis improves; Teva at parity
|
3/27/2015 | PP | Market Commentary: BioMarin As gain on swap, BioMarin Bs in line amid takeout rumors; health care better bid
|
3/27/2015 | CV | Market Commentary: BioMarin As gain on swap, BioMarin Bs in line amid takeout rumors; health care better bid
|
2/3/2015 | PP | Market Commentary: Isis adds on hedge after drug data disappoints; LinkedIn adds outright, on hedge
|
2/3/2015 | CV | Market Commentary: Isis adds on hedge after drug data disappoints; LinkedIn adds outright, on hedge
|
2/3/2015 | CV | Market Commentary: Morning Commentary: LinkedIn adds outright, on hedge; Isis Pharmaceuticals lower outright
|
1/5/2015 | PP | Market Commentary: Convertibles steady as equities sell off; volumes still low; Isis adds with stock on J&J deal
|
1/5/2015 | CV | Market Commentary: Convertibles steady as equities sell off; volumes still low; Isis adds with stock on J&J deal
|
1/5/2015 | CV | Market Commentary: Morning Commentary: Isis trades up in line with shares on J&J deal; oil drags markets lower
|
12/31/2014 | CV | Market Commentary: Outlook 2015: U.S. convertibles primary notches multi-year high; volume expected to climb
|
12/16/2014 | PP | Market Commentary: Convertibles weaken further amid market turmoil; Lukoil drops; technology names lower
|
12/16/2014 | CV | Market Commentary: Convertibles weaken further amid market turmoil; Lukoil drops; technology names lower
|
12/16/2014 | CV | Market Commentary: Morning Commentary: Convertibles weaken further amid market turmoil; Lukoil drops
|
12/15/2014 | PP | Market Commentary: American Realty lower; Isis Pharmaceuticals paper drops outright, ‘comes in’ on hedge
|
12/15/2014 | CV | Market Commentary: American Realty lower; Isis Pharmaceuticals paper drops outright, ‘comes in’ on hedge
|
11/21/2014 | CV | Isis greenshoe exercise lifts 1% seven-year convertibles $425 million
|
11/12/2014 | PP | Market Commentary: New Isis Pharmaceuticals trades below par, slips on hedge; Dendreon steady; Home Inns adds
|
11/12/2014 | CV | Market Commentary: New Isis Pharmaceuticals trades below par, slips on hedge; Dendreon steady; Home Inns adds
|
11/12/2014 | CV | Market Commentary: Morning Commentary: New Isis trades below par, slips on hedge; Dendreon trading at 55.5
|
11/12/2014 | CV | New Issue: Isis Pharmaceuticals prices $425 million seven-year convertibles to yield 1%, up 30%
|
11/11/2014 | CV | Market Commentary: Existing Isis bonds, shares up; planned Isis looks slightly rich; Ascent Capital shares drop
|
11/11/2014 | CV | Market Commentary: Morning Commentary: Planned Isis looks slightly rich, shares jump; Ascent Capital shares drop
|
11/10/2014 | PP | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
11/10/2014 | CV | Market Commentary: Dendreon drops after bankruptcy filing; Salix recoups some; Isis Pharmaceuticals on tap
|
11/10/2014 | CV | Isis Pharmaceuticals to price $425 million seven-year convertibles to yield 0.5%-1%, up 30%-35%
|
8/26/2014 | CV | Market Commentary: Priceline, Illumina trade in line; Medivation, Isis in focus; Prospect Capital bid lower
|
12/31/2013 | CV | Outlook 2014: U.S. secondary market poised for continued strength, but investors eye Fed taper
|
9/23/2013 | CV | Market Commentary: Convertibles mostly in line with lower shares; gold names in focus; Isis edges up on hedge
|
9/13/2012 | CVLM | Isis Pharmaceuticals redeems all $162.5 million convertibles due 2027
|
8/13/2012 | CVLM | Isis Pharmaceuticals calls $162.5 million all convertibles due 2027
|
8/10/2012 | CV | Market Commentary: MGM better on outright demand; Janus adds on investment stake; Hornbeck trades up, in line
|
8/9/2012 | CV | Market Commentary: New Exelixis gains on debut; new Prospect Capital prices at a discount; Medicis better
|
8/8/2012 | CV | New Issue: Isis Pharmaceuticals sells $201.25 million seven-year convertibles at 2.75%, up 32.5%
|
8/8/2012 | CV | Market Commentary: Isis pops on debut; older paper slips again; new Hornbeck adds; Tyson comes 'in' slightly
|
8/7/2012 | CV | Isis Pharmaceuticals revises talk on $175 million seven-year convertibles to 2.75%, up 32.5%
|
8/7/2012 | CV | Market Commentary: Existing Isis drops amid new deal, call; planned Isis price talk revised; Kodak falls
|
8/6/2012 | CV | Isis Pharmaceuticals offers $175 million seven-year convertibles at 3%-3.5%, up 27.5%-32.5%
|
8/6/2012 | CV | Market Commentary: Knight extends strong gains on capital infusion; Isis moves up with shares, launches deal
|
8/6/2012 | CVLM | Isis Pharma may buy back 2.625% convertibles using offer proceeds
|
7/9/2012 | CV | Market Commentary: Central European jumps 8-9 points outright; Molina Healthcare comes in 2 points on hedge
|
7/5/2012 | CV | Market Commentary: Convertibles market quiet; Navistar steady before conference call; Patriot Coal around 30
|
6/27/2012 | CV | Market Commentary: High-grade names in focus; Lennar adds; Isis under pressure; Gevo to price $30 million
|
5/21/2012 | CV | Market Commentary: Kodak collapses on patent ruling; lesser credits weak; Newmont expands; SanDisk active
|
3/1/2010 | CV | Market Commentary: Millipore a little weaker dollar neutral, but OSI Pharma expands; Amylin, Isis also in trade
|
1/8/2008 | CV | Market Commentary: Countrywide bashed on bankruptcy rumors, financials suffer; UAL, AMR, airlines squashed; ISIS surges
|
10/10/2007 | CV | Market Commentary: Molson Coors continues hot streak; Countrywide edges up; ISIS, Level 3 fall; Rayonier, iStar set to play
|
6/28/2007 | SP | New Issue: ABN Amro prices $1.5 million 22.4% knock-in notes linked to Isis Pharmaceuticals
|
6/4/2007 | SP | ABN Amro plans 22.4% reverse exchangeables linked to Isis Pharmaceuticals
|
4/12/2007 | CV | Isis Pharmaceuticals calls all of 51/2% convertibles due 2009
|
1/29/2007 | SP | New Issue: Credit Suisse sells $623,000 of 19% reverse convertibles linked to Isis
|
1/24/2007 | CV | Isis greenshoe fully exercised, upping convertibles to $142.5 million
|
1/18/2007 | CV | New Issue: Isis prices $125 million 20-year convertibles within talk, at 2.625%, up 30%
|
1/18/2007 | CV | Market Commentary: Lehman ends commissions for clients; Isis jumps on debut; National Financial makes quiet start
|
1/17/2007 | CV | Market Commentary: Headwaters rises at start; Vornado flat on rumors; Washington quiet; Isis, National Financial reviews differ
|
1/16/2007 | SP | Credit Suisse to price 19% notes linked to Isis Pharmaceuticals
|
1/16/2007 | CV | Isis to price $125 million 20-year convertibles Wednesday, talked at 2.5%-3%, up 27.5%-32.5%
|
1/16/2007 | CV | Market Commentary: Genesis soars on buyout; Symantec falls outright on warning; Headwaters strong in gray; issuance picks up
|
1/16/2007 | CV | Isis Pharmaceuticals plans to redeem remaining 5.5% convertibles
|
11/2/2006 | BT | Isis reports loss from operations of $18.3 million, resources sufficient through end of 2008
|
10/3/2006 | BT | Market Commentary: Acorda shoots up 32%; Isis lower after analyst day; Gilead off 3.5%, Myogen eases; Amgen better
|
10/3/2006 | BT | Isis predicts Ibis division profitability by 2010, gets government contracts for T5000
|
9/20/2006 | BT | Isis gets patent for pathogen identification
|
8/3/2006 | BT | Isis reports $2.17 million second quarter net loss
|
7/31/2006 | BT | Bruker, Isis form agreement for biosensor system
|
7/19/2006 | BT | Market Commentary: Amgen up slightly ahead of earnings; Isis, NeoPharm, Genta up; Affymetrix off, Illumina up 29%
|
6/13/2006 | BT | Isis: Three-month diabetes data shows consistent glucose improvement
|
6/12/2006 | BT | Isis says multiple antisense drugs show potential as treatments for metabolic disorders
|
6/12/2006 | BT | Isis' antisense drugs produce 'compelling' preclinical data in animal studies
|
6/1/2006 | BT | Isis receives orphan-drug status for ISIS 301012 to treat rare high cholesterol disease
|
5/31/2006 | BTPP | Isis Pharmaceuticals chief says $75 million equity line an 'insurance policy' in down market
|
5/31/2006 | BTPP | New Issue: Isis Pharmaceuticals releases terms of $75 million equity line
|
5/30/2006 | BT | Market Commentary: Cubist new convertible emerges; Vical zooms; Isis climbs; ISTA off despite news; CollaGenex climbs
|
5/30/2006 | PP | Market Commentary: Isis seals $75 million equity line; Vical wraps first tranche of stock deal as part of R&D agreement
|
5/30/2006 | BTPP | Isis Pharmaceuticals obtains $75 million equity line
|
4/27/2006 | BT | Isis Pharma's ISIS 301012 antisense drug reduces 'bad' cholesterol, total cholesterol in phase 2 trial
|
4/27/2006 | BT | ISIS 301012 shown to reduce atherosclerotic plaques in animal models
|
4/27/2006 | BT | Market Commentary: Acadia sinks with stock float on deck; Human Genome gains 9%; Isis gains big on data; Ark rises
|
4/18/2006 | BT | Isis Pharmaceuticals licenses anti-HIV drug to ImQuest Pharmaceuticals
|
4/11/2006 | BT | Market Commentary: NitroMed, Antigenics strike new lows; NPS Pharma, Insmed gain; Medtronic deal boosts Biomet
|
4/7/2006 | BT | Isis Pharmaceuticals, Symphony Capital enter into $75 million product development collaboration
|
3/28/2006 | BT | Market Commentary: Advanced Magnetics gains 7%; Xoma slides; Seattle Genetics deal surfaces; Cephalon dips 2%
|
3/27/2006 | BT | Isis Pharmaceuticals receives another antisense patent
|
2/22/2006 | BT | Isis, Rosetta Genomics to collaborate on microRNA-related liver cancer therapies
|
2/9/2006 | BT | Isis' data shows that Isis 301012 significantly reduces triglycerides
|
2/9/2006 | BT | Isis' data shows that Isis 301012 significantly reduces triglycerides
|
2/8/2006 | CV | Market Commentary: Citadel retraces some gains; Qwest flat but adds on hedge; MGI better; Oil States lower; Pier 1 prices
|
2/7/2006 | BT | Isis: Oral form of ISIS 301012 reduces cholesterol in humans
|
2/6/2006 | BT | Isis starts phase 2 program of ISIS 301012 in patients with familial hypercholesterolemia
|
2/6/2006 | BT | Market Commentary: OSI Pharma players debate new policy; Serono slips as 'for sale' sign stands; CuraGen gains 11%
|
2/1/2006 | CV | Market Commentary: JetBlue, Pixelworks down on earnings, but Cymer up; Schlumberger drops
|
2/1/2006 | BT | Lilly begins trials of anti-tumor drug; Isis to receive $750,000 milestone
|
2/1/2006 | BT | Market Commentary: Vertex gains; SGX debuts higher; Angiotech up; Alnylam off; DUSA dives; Endo slides; Isis bounces
|
1/31/2006 | BT | Isis Pharmaceuticals licenses antibiotics to Achaogen for $1.5 million in stock
|
12/22/2005 | BT | Isis Pharmaceuticals files $200 million shelf
|
11/7/2005 | BT | Isis Pharmaceuticals starts phase 2 ISIS 301012 study for cardiovascular disease
|
10/18/2005 | BT | Isis Pharmaceuticals gets $7 million from Drug Royalty USA
|
9/15/2005 | BT | Isis reiterated by Stanford Group at buy
|
9/8/2005 | BT | Market Commentary: Myogen, NPS float follow-ons; Nektar halted during FDA panel; Sepracor up in face of generic filing
|
8/26/2005 | BT | Market Commentary: AtheroGenics joins Amylin in gains linked to takeover chatter; Isis easier; DOV Pharma dives
|
8/24/2005 | BT | Isis retained by Global Crown at overweight
|
8/22/2005 | PP | Market Commentary: Isis Pharmaceuticals secures $51 million in stock sale; PIPE volume regains some momentum
|
8/22/2005 | BTPP | New Issue: Isis Pharmaceuticals raises $51 million in private placement of stock
|
8/12/2005 | BT | Market Commentary: Electro-Optical seen pricing Tuesday; Coley, China Medical mixed; Alexion slips; Isis convertible bid up
|
8/8/2005 | BT | Isis Pharmaceuticals converts Eli Lilly $100 million loan to 2.5 million shares
|
8/8/2005 | BT | Market Commentary: Isis declines on earnings, Lilly note conversion but 5.5% convert finds bids; Quest, LabOne higher
|
8/5/2005 | BT | Isis maintained by Stanford Group at buy
|
8/2/2005 | BT | Isis maintained by Stanford at buy
|
8/2/2005 | BT | Market Commentary: Anadys up on Novartis details; Ariad, Nastech, ZymoGenetics mixed; Myogen zooms; Isis gains
|
7/21/2005 | BT | Market Commentary: Adams IPO zooms; Accentia stalls, again; Guilford up on MGI Pharma merger; Momenta on tap; Isis rises
|
7/15/2005 | CV | Market Commentary: Chiron drops as convertibles market trades mostly flat to lower; but CV Therapeutics, Isis gain
|
7/14/2005 | BT | Market Commentary: Genentech active; CryoCor IPO trades up, sinks; Mylan prices tight, center; BioMarin off on follow-on
|
1/12/2005 | CV | Market Commentary: Level 3 higher on job cuts; CenturyTel off; Kodak up; Advanced Micro rebounds
|
3/17/2003 | CV | Market Commentary: Markets go green on war visibility; spate of deals hold promise for busy week
|
6/12/2002 | CV | Deutsche on biopharma: buy Inhale, Cell Therapeutics; hold Abgenix, Alexion; sell Vertex, ISIS
|
5/17/2002 | CV | Market Commentary: LifePoint gains in hungry market; El Paso drops on "bad" news
|
4/26/2002 | CV | New Issue: Isis Pharma $125 million convertibles at 5.5% yield, up 25%
|
4/26/2002 | CV | Market Commentary: New issues lower with broader market; Alltel launches $1.25 billion
|
4/25/2002 | CV | Market Commentary: Market declines on earnings, events; new issues trickle in
|
4/25/2002 | HY | Tenders
|
4/24/2002 | CV | Isis Pharmaceuticals to use $74 million of convertibles proceeds to retire 14% notes
|
4/24/2002 | CV | Market Commentary: Calpine, Tyco active on fresh round of news, Waste Connections sells floater
|
4/23/2002 | CV | ISIS Pharmaceuticals $125 million convertibles talked at 5.0-5.5% yield, up 20-25%
|
4/23/2002 | CV | Market Commentary: New issues invigorate otherwise languid market; Calpine seen heading south
|